SCHEMBL4073593

SCHEMBL4073593

c1snnc1-c1nnns1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.41
KMT2A Q03164 3/20 0.41
NPC1 O15118 3/20 0.41
MEN1 O00255 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
POLB P06746 2/20 0.41
NOTUM Q6P988 1/20 0.41
LMNA P02545 2/20 0.38
ALDH1A1 P00352 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36
HPGD P15428 1/20 0.36
CYP2C19 P33261 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
CDC25A P30304 1/20 0.33
CDC25B P30305 1/20 0.33
CDC25C P30307 1/20 0.33
MAPT P10636 1/20 0.32
PKM P14618 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL445070 0.61 KMT2A (0.38) RAB9AKMT2ANPC1MEN1SMN1; SMN2
SCHEMBL9465141 0.61 RAB9A (0.42) RAB9AKMT2ANPC1MEN1SMN1; SMN2
SCHEMBL69349 0.60 KMT2A (0.91) RAB9AKMT2ANPC1MEN1SMN1; SMN2
SCHEMBL28929770 0.59 KMT2A (0.45) RAB9AKMT2ANPC1MEN1SMN1; SMN2
SCHEMBL28750518 0.58 KMT2A (0.63) RAB9AKMT2ANPC1MEN1SMN1; SMN2
SCHEMBL28576782 0.58 RAB9A (0.64) RAB9AKMT2ANPC1MEN1SMN1; SMN2
SCHEMBL28615396 0.58 KMT2A (0.64) RAB9AKMT2ANPC1MEN1SMN1; SMN2
SCHEMBL558024 0.58 KMT2A (0.64) RAB9AKMT2ANPC1MEN1SMN1; SMN2
SCHEMBL30661946 0.57 KDM4E (0.58) RAB9AKMT2ANPC1MEN1SMN1; SMN2
SCHEMBL21408743 0.57 KMT2A (0.52) RAB9AKMT2ANPC1MEN1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7482355-B2 Asthma, antiallergens; rheumatoid arthritis and atherosclerosis; 2-(Benzylthio)-6-{[(1R)-2-hydroxy-1-methylethyl]amino}-4-pyrimidinol ASTRAZENECA AB (SE) 2009-01-27 US claimed
US-20060004030-A1 Pyrimidine derivatives as modulators of chemokine receptor activity ASTRAZENECA AB (SE) 2006-01-05 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004030-A1 Pyrimidine derivatives as modulators of chemokine receptor activity CXCR2, CXCR1, ACKR3 RAB9A 1876/4885KMT2A 4750/4885NPC1 1665/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.